29c49da8-3d12-425d-abe6-de2be5e6807f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.280
- PROTEIN_SECRETION+0.200
- G2M_CHECKPOINT+0.180
- INTERFERON_GAMMA_RESPONSE+0.180
- MITOTIC_SPINDLE+0.160
- ANDROGEN_RESPONSE+0.120
- INFLAMMATORY_RESPONSE+0.120
- INTERFERON_ALPHA_RESPONSE+0.100
- ALLOGRAFT_REJECTION+0.060
- APICAL_SURFACE+0.030
Top 10 suppressed
- MYC_TARGETS_V2-0.510
- OXIDATIVE_PHOSPHORYLATION-0.410
- HEDGEHOG_SIGNALING-0.370
- WNT_BETA_CATENIN_SIGNALING-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- UV_RESPONSE_UP-0.300
- MYC_TARGETS_V1-0.280
- PANCREAS_BETA_CELLS-0.250
- CHOLESTEROL_HOMEOSTASIS-0.240
- PI3K_AKT_MTOR_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650133 | — | — | 0.727 |
| 2 | b9389390-aa03-406c-957e-2bc264f9468e | — | — | 0.717 |
| 3 | TCGA-DK-A3IV-01A-22R-A21D-07 | — | — | 0.705 |
| 4 | TCGA-OR-A5LT-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.704 |
| 5 | TCGA-55-7727-01A-11R-2170-07 | — | cohortMD2 | 0.699 |
| 6 | SRR2932842 | — | — | 0.693 |
| 7 | TCGA-78-7143-01A-11R-2039-07 | — | cohortA1 | 0.687 |
| 8 | 5b217223-8b43-47b6-a694-c808b643c3c3 | — | — | 0.687 |
| 9 | TCGA-P3-A5QE-01A-11R-A28V-07 | — | — | 0.680 |
| 10 | TCGA-BA-5559-01A-01R-1514-07 | — | — | 0.672 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.060 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |